Cervical Cancer Screening — Coverage Criteria
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Coverage criteria and clinical background for cervical cancer screening tests (Pap cytology, high-risk HPV testing, co-testing, and related follow-up) for individuals with a cervix under Blue Cross Blue Shield - Tennessee benefits.
No material clinical or coverage changes in this revision.
Coverage Criteria for Cervical Cancer Screening
Routine screening coverage criteria
Covered when the following age- and risk-based conditions are met
From policy: includes organ transplant, immunocompromised, IBD on immunosuppressants, etc.
Applies to immunocompetent, asymptomatic individuals with a cervix.
Selection among listed options allowed per USPSTF/ACS guidance.
High‑risk exceptions to routine cessation of screening.
Genotype‑specific reflex testing supported.
Annual surveillance specified for these indications.
Not covered routine screening
Situations where screening does NOT meet coverage
Applies to asymptomatic, average‑risk individuals; initial screening for HIV is an exception (see HIV criteria).
Describes criteria to stop routine screening per USPSTF/ACS guidance.
Complete hysterectomy with cervix removed and no prior disease excludes screening.
Policy explicitly lists these as not covered.
Screening in HIV-positive individuals
HIV-positive individuals — distinct screening cadence
HIV‑specific initiation guidance per Robinson 2023a.
Preference for cytology in this age group.
HPV‑alone contraindicated for HIV‑positive >=30 per policy.
Long‑term lifetime screening recommended for HIV‑positive individuals.
General population screening
Covered when following guideline-recommended age ranges and intervals
Per USPSTF, ACS, and related guideline recommendations.
ACS screening recommendations
American Cancer Society preferred approach
ACS 2020 guideline updates (Fontham et al., 2020).
Immunocompromised screening
Special-population screening recommendations (immunocompromised, transplant, IBD on immunosuppressants)
ASCCP 2019 / Moscicki et al. guidance for non‑HIV immunocompromised populations.
Post-treatment surveillance
Surveillance after treatment for high-grade lesions
Risk remains elevated long‑term; follow ASCCP/ASCO/ACOG recommendations.
ASCO maximal-resource guidance
ASCO resource-stratified recommendations for maximal-resource settings
ASCO 2022 maximal‑resource guidance.
Resource-stratified screening and management
Covered when following resource-stratified criteria are met:
ASCO guidance for maximal‑resource settings.
Enhanced‑resource recommendations and reimbursement policy details.
Limited‑resource guidance per ASCO/Policy.
Basic‑resource ASCO recommendations.
Precursor lesion treatment and follow-up
Covered when ALL of the following are met for precursor lesions:
ASCO recommends LEEP or ablative options per resource/context.
ASCO follow‑up recommendation; if 12‑month positive continue annual surveillance.
This policy explicitly excludes the inclusion of low-risk HPV strains when performing co-testing for cervical cancer screening and excludes unspecified novel technologies lacking sufficient evidence. The policy lists low-risk HPV types in co-testing and "other technologies for cervical cancer screening" under items that do not meet coverage criteria, reflecting insufficient clinical evidence to support their routine use for screening.
Routine screening does not meet coverage for individuals without a cervix after hysterectomy for benign disease, for individuals younger than 21 years, and for individuals older than 65 years who have an adequate prior screening history. The policy defines adequate prior screening as either three consecutive negative Pap smears or two consecutive negative HPV tests within the prior 10 years with the most recent within 5 years. The National Cancer Institute guidance cited similarly states that screening is not helpful in persons who do not have a cervix after hysterectomy for benign conditions.
If an applicable government policy (for example, a Local Coverage Determination, a National Coverage Determination for Medicare, or state Medicaid coverage) conflicts with this policy, the government policy governs the coverage determination. Providers should consult the relevant CMS or state Medicaid resources for the most current applicable government coverage rules.
The policy references current guideline and primary literature sources (including NCCN, NCI, USPSTF, ASCO, and trial reports such as the HPV FOCAL randomized trial) in its bibliography. These references provide the evidentiary context for the age- and risk-based recommendations and do not, in themselves, add additional exclusions beyond those stated in the policy.
Routine screening cessation and age-based caveats: screening is not covered for individuals younger than 21 years. For individuals older than 65 years who are not high-risk and who have an adequate screening history (three consecutive negative Pap smears or two negative HPV tests within 10 years with the most recent within 5 years), routine screening does not meet coverage criteria. High-risk individuals (>65) — including prior high-grade precancer or cancer, in utero DES exposure, or immunocompromised status — remain eligible for coverage beyond usual cessation ages.
The USPSTF recommendation summarized in this policy states that screening for cervical cancer is recommended (Grade A) for ages 21 to 65 with specified intervals, and it recommends against screening for women younger than 21 and for women older than 65 who have had adequate prior screening (Grade D). The policy cites the USPSTF grade assignments to support the age-based coverage determinations.
The document notes that many laboratories perform laboratory-developed tests (LDTs) which are regulated under CLIA ’88 as high-complexity tests. It clarifies that these LDTs are not FDA-approved or -cleared but are widely used clinically and governed by CMS/CLIA requirements; the policy does not make explicit statements declaring LDTs medically unnecessary.
The policy excerpts provided do not include standalone statements labeling specific services as not medically necessary beyond the age-, hysterectomy-, and risk-based exclusions already described. While the document discusses regulatory status of LDTs and cites evidence sources, these sections do not add separate 'not medically necessary' declarations.
Coding and Screening Interval Thresholds
| 87623 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), low-risk types (e.g., 6, 11, 42, 43, 44). |
| 87624 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68). |
| 87625 | Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only, includes type 45, if performed. |
| 88141 | Cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician. |
| 88142 | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision. |
| 88143 | Cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation; with manual screening and rescreening under physician supervision. |
| 88147 | Cytopathology smears, cervical or vaginal; screening by automated system under physician supervision. |
| 88148 | Cytopathology smears, cervical or vaginal; screening by automated system with manual rescreening under physician supervision. |
| 88150 | Cytopathology, slides, cervical or vaginal; manual screening under physician supervision. |
| 88152 | Cytopathology, slides, cervical or vaginal; with manual screening and computer-assisted rescreening under physician supervision. |
| G0141 | Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician. |
| G0143 | Screening cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation, with manual screening and rescreening by cytotechnologist under physician supervision. |
| G0144 | Screening cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation, with screening by automated system, under physician supervision. |
| G0145 | Screening cytopathology, cervical or vaginal, collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision. |
| G0147 | Screening cytopathology smears, cervical or vaginal, performed by automated system under physician supervision. |
| G0148 | Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening. |
| G0476 | Infectious agent detection by nucleic acid (DNA or RNA); human papillomavirus (HPV), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test. |
| P3000 | Screening Papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision. |
| P3001 | Screening Papanicolaou smear, cervical or vaginal, up to three smears, requiring interpretation by physician. |
| Q0091 | Screening Papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory. |
Provider Actions, Documentation, and Billing
Prior Authorization and Government Policy Precedence
Prior authorization: No specific prior authorization requirements or codes are stated in this policy. Coverage is determined by meeting the clinical criteria in the policy and by the member's benefit coverage at the time of service.
- If conflict with applicable government policy (LCD/NCD/state Medicaid) exists, the government policy governs (see Applicable State and Federal Regulations).
Billing Codes for HPV and Cytology Testing
Billing and coding: Use the listed CPT/HCPCS procedure codes when requesting reimbursement for HPV testing, genotyping, and cervical cytology services. Document the codes used on the claim and in the medical record.
Coverage Exclusions by Age and Hysterectomy Status
Coverage exclusions and age/hysterectomy limitations: Screening that does not meet guideline-based indications may be denied. Specifically, routine cervical cancer screening DOES NOT MEET COVERAGE CRITERIA for individuals younger than 21 years, for individuals over 65 years who are not high-risk with an adequate screening history, and for individuals who have had a total hysterectomy with removal of the cervix and have no history of cervical cancer or precancer.
- Do not screen individuals <21 years unless guideline-specified indication applies.
- Do not routinely screen individuals >65 years with an adequate screening history (defined in policy).
- Do not screen individuals post-hysterectomy with no prior cervical cancer or precancer history.
Documentation Requirements to Support Coverage
Required documentation to support coverage: Providers should document the member's age, risk status (including immunosuppression, organ transplant, DES exposure, prior HSIL/CIN or cervical cancer), prior screening history (dates and results of prior Pap and HPV tests), and the clinical indication for testing. Also document use of the specific procedure codes when submitting claims.
- Record prior screening history and any abnormal results that affect management.
- Document risk factors that make the patient high-risk and justify more frequent screening.
- Include the specific CPT/HCPCS codes used for the performed tests in clinical notes and on the claim.
Clinical Management Sequence and Step Therapy
Clinical management sequence and step therapy: There is no step therapy requirement specified. Clinical management follows a sequence: primary HPV testing → reflex genotyping and/or cytology triage from the same specimen → referral to colposcopy/biopsy if triage is abnormal. For primary HPV-positive/cytology-negative results, reflex genotyping for HPV-16/18 (and HPV-45 where referenced) or cytology triage is recommended; if genotyping is positive and reflex testing cannot be performed on the same specimen, proceed directly to colposcopy. Repeat HPV testing at 12 months is recommended when triage is negative, with referral to colposcopy if persistent positivity occurs.
- No step therapy or quantity limits are defined in the policy.
- All positive primary HPV tests should have reflex triage testing performed from the same specimen when feasible.
- Triage abnormality (>ASC-US or HPV 16/18 positive) → refer to colposcopy/biopsy.
- Triage negative → repeat HPV at 12 months; if still positive at 12 months → colposcopy.
References and Provider Guidance
References and bibliography: This section contains bibliographic references that inform the clinical recommendations and coverage criteria. The references do not impose additional prior authorization or documentation requirements beyond those stated in this policy.
- Selected references include guidelines and studies from NCCN, ASCO, NCI, USPSTF, and peer-reviewed literature listed in the policy's reference section.
Clinical Background and Rationale
Background: Cervical cancer screening aims to detect cervical precancerous lesions and cancer using cytology (Pap), high-risk HPV nucleic acid testing, and colposcopy/biopsy when indicated. The policy bases recommendations on established guideline frameworks and trial evidence, outlining screening modalities (Pap smear sampling of the ectocervix and endocervix, high-risk HPV NAATs) and the role of triage (reflex genotyping and cytology) and colposcopy for abnormal results.
Definitions and Key Terms
Revision History and References
The references cited include guideline documents and key studies used to support the policy (for example, NCCN 2023, USPSTF 2018, ASCO guidance, Moscicki et al. 2019 for immunosuppressed women, and clinical trials such as the HPV FOCAL randomized trial). These bibliographic citations form the evidence base for the age- and risk-based coverage criteria and follow-up recommendations described in the policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.